Evidence map›Paper›PMID 41190437›Full record

ArticleCirculation. Genomic and precision medicine2025

Rare Variants in HTRA1, SGTB, and RBM12 Confer Risk of Atherosclerotic Cardiovascular Disease Independent of Traditional Cardiovascular Risk Factors.

Sam M Lockhart, Anuradhika Puri, Yajie Zhao, Vladimir Saudek, Eugene J Gardner, Katherine A Kentistou, Brian Y H Lam, Felix R Day, Stephen O'Rahilly, John R B Perry and 2 more

Abstract read
In one paragraph

Article in Circulation. Genomic and precision medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Genetic factors contributing to atherosclerosis.Current opinion in cardiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sam M Lockhart *Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, United Kingdom (S.M.L.).ORCID 0000-0003-2092-4350
Anuradhika Puri *Department of Chemistry, Washington University, St. Louis, MO (A.P., M.E.J.).ORCID 0000-0002-3642-728X
Yajie ZhaoMRC Epidemiology Unit, Institute of Metabolic Science (Y.Z., E.J.G., K.A.K., F.R.D., J.R.B.P., K.K.O., J.R.B.P.), University of Cambridge, United Kingdom.ORCID 0000-0002-2747-0219
Vladimir SaudekMetabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science (S.M.L., V.S., S.O., B.Y.H.L.), University of Cambridge, United Kingdom.ORCID 0000-0003-4980-9057
Eugene J GardnerMRC Epidemiology Unit, Institute of Metabolic Science (Y.Z., E.J.G., K.A.K., F.R.D., J.R.B.P., K.K.O., J.R.B.P.), University of Cambridge, United Kingdom.
Katherine A KentistouMRC Epidemiology Unit, Institute of Metabolic Science (Y.Z., E.J.G., K.A.K., F.R.D., J.R.B.P., K.K.O., J.R.B.P.), University of Cambridge, United Kingdom.
Brian Y H LamMetabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science (S.M.L., V.S., S.O., B.Y.H.L.), University of Cambridge, United Kingdom.ORCID 0000-0002-3638-9025
Felix R DayMRC Epidemiology Unit, Institute of Metabolic Science (Y.Z., E.J.G., K.A.K., F.R.D., J.R.B.P., K.K.O., J.R.B.P.), University of Cambridge, United Kingdom.ORCID 0000-0003-3789-7651
Stephen O'Rahilly *Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science (S.M.L., V.S., S.O., B.Y.H.L.), University of Cambridge, United Kingdom.ORCID 0000-0003-2199-4449
John R B Perry *MRC Epidemiology Unit, Institute of Metabolic Science (Y.Z., E.J.G., K.A.K., F.R.D., J.R.B.P., K.K.O., J.R.B.P.), University of Cambridge, United Kingdom.
Ken K Ong *Department of Paediatrics (K.K.O.), University of Cambridge, United Kingdom.ORCID 0000-0003-4689-7530
Meredith E Jackrel *Department of Chemistry, Washington University, St. Louis, MO (A.P., M.E.J.).ORCID 0000-0003-4406-9504

Funding

Elucidating the roles of protein disaggregases and developing enhanced diaggregases to counter diverse protein-misfolding disordersR35GM153303 · NIGMS · WASHINGTON UNIVERSITY · PI Meredith E. Jackrel · 2024 to 2026
$1.4M
Medical Research Council MC_UU_00006/2NIGMS NIH HHS R35 GM153303Wellcome Trust 225479
6 · The paper itself

Abstract

backgroundAtherosclerosis is a pathophysiological process common to a range of cardiovascular diseases. We reasoned that considering clinical presentations of atherosclerosis across the coronary, peripheral, and cerebrovasculature as a single entity would enhance statistical power to identify rare genetic variation driving pathological processes across multiple vascular beds.

methodsWe performed an exome-wide association study of atherosclerotic cardiovascular disease in 434 438 UK Biobank participants of European ancestry.

resultsWe identified rare, predicted damaging variants in HTRA1, SGTB, and RBM12 to be associated with risk of atherosclerotic cardiovascular disease, independent of known risk factors. Both SGTB and HTRA1 were downregulated in the aorta of patients with coronary artery disease compared with controls. Loss-of-function variants in the RNA-binding protein RBM12 increased the risk of coronary, cerebrovascular, and peripheral vascular diseases to a similar extent. SGTB increased the risk of atherosclerotic cardiovascular disease in the coronary and peripheral circulations but not the cerebrovasculature. While loss-of-function variants in HTRA1 are known to cause monogenic stroke syndromes, we found that damaging missense variants in HTRA1 are associated with increased risk of disease in both the cerebrovascular and coronary circulation. Surprisingly, the increased risk of coronary artery disease was driven predominantly by a single missense variant (p.R227W; minor allele frequency, 0.009). In vitro, the R227W mutant HTRA1 efficiently proteolyzed the disordered substrate casein but not aggregated α-synuclein. In contrast, a stroke risk-raising variant (D320N) could not efficiently process any of the tested substrates.

conclusionsWe identified novel genetic variants predisposing to atherosclerotic cardiovascular diseases that act independently of established cardiovascular risk factors. The observed phenotypic and functional heterogeneities between HTRA1 variants suggest that distinct biochemical mechanisms drive HTRA1-related vascular disease in the brain and heart.

Indexed as

AtherosclerosisHigh-Temperature Requirement A Serine Peptidase 1RNA-Binding ProteinsAgedCardiovascular DiseasesCoronary Artery DiseaseFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedRisk FactorsHigh-Temperature Requirement A Serine Peptidase 1HTRA1 protein, humanRNA-Binding Proteinsatherosclerosiscardiovascular diseasesmyocardial ischemiastroke

Identifiers

PMID41190437
PMCPMC7618418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.